Key result
Targeted therapy with methylprednisolone or eltrombopag successfully increased platelet counts to safe levels, allowing for successful coronary stenting and dual antiplatelet therapy without hemorrhagic complications in patients with immune thrombocytopenia.
Why the study?
Immune thrombocytopenia in patients with cardiovascular disorders requiring antiplatelet and anticoagulant therapy increases the risk of hemorrhages and thromboembolic complications, requiring special management.
Case Report (n=2)
No
Answers are grounded in this paper and cite their sources.
A multidisciplinary approach involving targeted ITP therapy to raise platelet counts enables safe coronary stenting and dual antiplatelet therapy in patients with concomitant immune thrombocytopenia and severe ischemic heart disease.
Immune thrombocytopenia in patients with concomitant cardiovascular disorders requiring antiplatelet and anticoagulant therapy can increase the risk of hemorrhages and arterial and venous thromboembolic complications. This situation necessitates special patient management. Multidisciplinary approach is important for patients requiring myocardial revascularization due to the necessity of administration of double or triple antiplatelet therapy.The article presents our experience in management of patients with immune thrombocytopenia and high functional class stable angina requiring coronary artery stent.
No takes yet. Share an insight, caveat, or question.
Ryabukhina et al. (2025) conducted a case report in Immune thrombocytopenia and ischemic heart disease (n=2). Methylprednisolone or Eltrombopag prior to coronary stenting was evaluated. Targeted therapy with methylprednisolone or eltrombopag successfully increased platelet counts to safe levels, allowing for successful coronary stenting and dual antiplatelet therapy without hemorrhagic complications in patients with immune thrombocytopenia.
Synapse has enriched 10 related papers. Consider them for comparative context: